Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine SR in adults with ADHD
NCT03605836Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: ADHD Investigator Symptom Rating Scale at Day 42. Started Jan 2019; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03605836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605836.